64 / 1084
3/28/2017
6
TheRoyalMarsden
Survival by CRM
O’Neill et al. BJS 2013; 100:1055-63
TheRoyalMarsden
CRM in Neoadjuvant Trials
CS
S
CF ECX CXRT S
OEO2 25% 28%
OEO5
41% 33%
CROSS
8% 30%
NutritionalaspectsofEnhancedRecovery
32
Radical Surgery – 13% - 2/62
TheRoyalMarsden
Positive margin vs negative margin
Pre-op Staging
Margin positive
Margin negative
T3N0
10%
T3N0 nor T1-2N0/1 40%
T3N1
40%
50%
T3N2
50%
10%
Median no +LN
5
0
Mean No +LN
6.3
1.6
Survival after Treatment for CRM+
O’Neill et al. BJS 2013; 100:1055-63
TheRoyalMarsden
Aim of Resection
Complete resection of primary tumour (R0)
Clear margins
Lymphadenectomy (>15 nodes)
35
Survival by Number examined in N0 Disease
Bollschweiller et al 2006
Bollschweiler et al 2006